Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

  • ID: 4403192
  • Report
  • Region: Global
  • 135 Pages
  • GBI Research
1 of 4

Summary

Cancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to other parts of the body. The diseases are driven by the accumulation of genetic mutations, which provide selective advantages to cells allowing them to evolve and propagate virtually all sites and tissues in the human body.

Cancer currently stands as the second leading cause of death in economically developed countries globally, surpassed only by heart disease (World Health Organization, 2017). Across the eight major developed markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) there were a total of 3.6 Million incident cases of cancer, and 11.2 Million five-year prevalent cases across the top 20 most common sites in 2012. Its prevalence across the globe presents a huge health burden, with over 14 Million new cases being diagnosed in 2012, with a five-year prevalence of 32.6 Million.

Approximately 26 Million new cancer cases and 17 Million cancer deaths per year are projected by 2030 (Ferlay et al., 2015). This increase in cancer incidence and mortality is forecast to be driven by population growth and aging across developed and developing countries, with the global population forecast to reach 8.3 billion by 2030.

The two most common cancers by five-year prevalence are prostate and breast cancers, with 696 and 686 prevalent cases per 500,000 respectively. These have 559,000 and 560,000 incident cases each year, respectively. The other most common cancers comprise a variety of sites across almost all organ systems, with only the CNS and skeletal system not being represented among the top 20 cancers by site.

The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report:

  • Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
  • Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Scope

  • The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?
  • There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
  • A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

  • Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking immunotherapeutic approaches to treating cancer indications with current poor prognoses, including melanoma and lung cancer.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents

2 Executive Summary
2.1 A Large Therapy Area with Varying Unmet Needs across Indications
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation

3 The Case for Innovation in the Oncology Market
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Epidemiology
4.1.2 Etiology
4.1.3 Pathophysiology
4.1.4 Diagnosis
4.1.5 Prognosis and Disease Staging
4.2 Treatment Options
4.2.1 Surgery
4.2.2 Radiation Therapy
4.2.3 Chemotherapy
4.2.4 Hormonal Therapies
4.2.5 Targeted Therapies
4.2.6 Immunotherapies
4.3 Overview of Marketed Products within Cancer Immunotherapy
4.4 Current Unmet Needs across the Oncology Markets

5 Assessment of Pipeline Product Innovation
5.1 Cancer Immunotherapies Pipeline by Phase, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.3.1 First-in-Class Cancer Immunotherapy Products by Phase, Molecule Type and Molecular Target

6 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.1 The Complexity of Signaling Networks in Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Target Matrix Assessment

7 First-in-Class Target Assessment
7.1 Pipeline Programs that Target Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
7.2 Pipeline Programs that Target Programmed Death 1 Ligand-2
7.3 Pipeline Programs that Target OX-2 Membrane Glycoprotein/CD200
7.4 Pipeline Programs that Target Killer-Cell Immunoglobulin-Like Receptors
7.5 Pipeline Programs that Target Toll-Like Receptors
7.6 Pipeline Programs that Target Inducible T-Cell Costimulator
7.7 Pipeline Programs that Target Membrane Cofactor Protein
7.8 Pipeline Programs that Target NKG2-A/NKG2-B Type II Integral Membrane Protein
7.9 Pipeline Programs that Target Stimulator of Interferon Genes Protein
7.10 Conclusion

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.2 Co-development Deals

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Research Methodology
9.3.1 Data Integrity
9.3.2 Innovative and Meaningful Analytical Technique and Frameworks
9.3.3 Evidence-based Analysis and Insight
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals

List of Tables
Table 1: Epidemiology by Top 20 Most Common Cancer Sites, 2012
Table 2: Epidemiology by Top 20 Most Common Cancer Sites, 2012
Table 3: Epidemiology by Top 20 Most Common Cancer Sites, 2012
Table 4: Epidemiology by Top 20 Most Common Cancer Sites, 2012
Table 5: TNM Staging, 2015
Table 6: Karnofsky Scores and Equivalent ECOG Staging, 2015
Table 7: Optimal and Actual Radiation Therapy Usage Rates in US, 1995-2000
Table 8: Top 10 Cancer Types According to Treatment Demand Criteria, 2017
Table 9: Cancer Immunotherapies, Low-Affinity Immunoglobulin Gamma Gc Region Receptor IIIA as a Therapeutic Target, 2017
Table 10: Cancer Immunotherapies, Programmed Cell Death 1 Ligand 2 as a Therapeutic Target, 2017
Table 11: Cancer Immunotherapies, OX-2 Membrane Glycoprotein/CD200 as a Therapeutic Target, 2017
Table 12: Cancer Immunotherapies, Killer-Cell Immunoglobulin-Like Receptors as a Therapeutic Target, 2017
Table 13: Cancer Immunotherapies, Toll-Like Receptors as a Therapeutic Target, 2017
Table 14: Cancer Immunotherapies, Inducible T-Cell Costimulator as a Therapeutic Target, 2017
Table 15: Cancer Immunotherapies, Membrane Cofactor Protein as a Therapeutic Target, 2017
Table 16: Cancer Immunotherapies, NKG2-A/NKG2-B Type II Integral Membrane Protein as a Therapeutic Target, 2017
Table 17: Cancer Immunotherapies, Stimulator of Interferon Genes Protein as a Therapeutic Target, 2017

List of Figures
Figure 1: Innovation Trends in Product Approvals, 1987-2013
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
Figure 3: Relative Survival Rates for the Top 20 Cancers by Site, 2014
Figure 4: Molecule Types and Molecular Targets of Marketed Products for Oncology, 2017
Figure 5: Molecule Types and Molecular Targets of Marketed Products within Cancer Immunotherapies, 2017
Figure 6: Summary of Five-Year Survival Rate, Incidence and Mortality by Site, 2012
Figure 7: Pipeline Products by Therapy Area, 2017
Figure 8: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecule Type, 2017
Figure 9: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecular Target, 2017
Figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2017
Figure 11: Summary of Incidence, Mortality, Mortality Rates and Cancer Immunotherapies Pipeline Activity by Tumor Site, 2015-2017
Figure 12: Comparison of First-in-Class to Established Products in the Cancer Immunotherapies Pipeline by Tumor Site, 2017
Figure 13: Overview of First-In-Class Cancer Immunotherapies Products, 2017
Figure 14: Percentage Distribution of First-in-Class to Established Products, Cancer Immunotherapies Pipeline, 2017
Figure 15: Molecular Target Category Comparison, Pipeline First-In-Class and Established Molecular Targets, 2017
Figure 16: Cancer Immunotherapies, Ratio of First-in-Class Pipeline Targets to First-in-Class Pipeline Products
Figure 17: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 1
Figure 18: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 2
Figure 19: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 3
Figure 20: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 4
Figure 21: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 5
Figure 22: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 6
Figure 23: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 7
Figure 24: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 8
Figure 25: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 9
Figure 26: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 10
Figure 27: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 11
Figure 28: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 12
Figure 29: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 13
Figure 30: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 14
Figure 31: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 15
Figure 32: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 16
Figure 33: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 17
Figure 34: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 18
Figure 35: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 19
Figure 36: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 20
Figure 37: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 21
Figure 38: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 22
Figure 39: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 23
Figure 40: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 24
Figure 41: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 25
Figure 42: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 26
Figure 43: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 27
Figure 44: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 28
Figure 45: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 29
Figure 46: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 30
Figure 47: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 31
Figure 48: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 32
Figure 49: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 1
Figure 50: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 2
Figure 51: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 3
Figure 52: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 4
Figure 53: Pipeline Programs Targeting Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
Figure 54: Pipeline Programs Targeting Programmed Cell Death 1 Ligand 2 (PD-L2)
Figure 55: Pipeline Programs Targeting OX-2 Membrane Glycoprotein/CD200
Figure 56: Pipeline Programs Targeting Killer-Cell Immunoglobulin-Like Receptors
Figure 57: Pipeline Programs Targeting Toll-Like Receptor 3
Figure 58: Pipeline Programs Targeting Toll-Like Receptor 6
Figure 59: Pipeline Programs Targeting Toll-Like Receptor 8
Figure 60: Pipeline Programs Targeting Inducible T-Cell Costimulator
Figure 61: Pipeline Programs Membrane Cofactor Protein
Figure 62: Pipeline Programs Targeting NKG2-A/NKG2-B Type II Integral Membrane Protein
Figure 63: Pipeline Programs Targeting Stimulator of Interferon Genes Protein
Figure 64: Cancer Immunotherapies, Global, Licensing Deals by Region and Value, 2006-Q1 2017
Figure 65: Cancer Immunotherapies, Global, Licensing Deals by Stage and Value, 2006-Q1 2017
Figure 66: Cancer Immunotherapies, Global, Licensing Deals by Molecule Type, 2006-Q1 2017
Figure 67: Cancer Immunotherapies, Global, Licensing Deals by Molecular Target, 2006-Q1 2017
Figure 68: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 1
Figure 69: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 2
Figure 70: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 3
Figure 71: Cancer Immunotherapies, Global, Co-development Deals by Region and Value, 2006-Q1 2017
Figure 72: Cancer Immunotherapies, Global, Co-development Deals by Stage and Value, 2006-Q1 2017
Figure 73: Cancer Immunotherapies, Global, Co-development Deals by Molecule Type, 2006-Q1 2017
Figure 74: Cancer Immunotherapies, Global, Co-development Deals by Molecular Target, 2006-Q1 2017
Figure 75: Cancer Immunotherapies, Global, Co-development Deals with Disclosed Values, 2006-Q1 2017
Figure 76: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 1
Figure 77: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 2
Figure 78: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 3
Figure 79: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 4
Figure 80: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 5
Figure 81: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 6
Figure 82: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 7
Figure 83: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 8
Figure 84: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 9
Figure 85: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 10
Figure 86: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 11

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll